US · Healthcare · Diagnostics & Research
EPS came in at 0.37 against a street estimate of 0.29 — a beat of 27.6%.
Analysts rate Veracyte Inc a buy (9 buy, 1 hold, 1 sell out of 11) with an average price target of $58.42.
CONFIDENT Veracyte delivered 15% revenue growth on strong Decipher and Afirma momentum, launching Prosigna LDT and TrueMRD. Raised 2026 guidance above prior range; maintaining 26%+ EBITDA. Early traction on new products encouraging but limited contribution this year. Q2 2026 No geographic breakdown provided on call. Analysts pressed on AI competition (no threat; different biology measured), Prosigna market share upside (entire ER+/HER2− addressable; early adoption metrics strong), and MRD pipeline timing (deferred specifics). Management conveyed confidence in launches but remained measured on guidance, citing pending reimbursement and early-stage revenue contribution. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.39% |
| FMR Inc | 9.66% |
| Artisan Partners Limited Partnership | 6.89% |
| State Street Corp | 6.27% |
| Vanguard Portfolio Management, LLC | 5.53% |
| Vanguard Capital Management, LLC | 4.39% |
| ARK Investment Management LLC | 3.80% |
| Dimensional Fund Advisors, Inc. | 3.52% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 VERACYTE, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Veracyte completed acquisition of Convergent Genomics Inc. on September 14, 2026 • Upfront cash | 2026-09-14 |
| Quarterly report · Q2 2026 VERACYTE, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (Q2 2026): $150.3 million (up 15% vs Q2 2025: $130.2 million) • Total Revenue | 2026-07-31 |
| Results announced · Q3 2026 VERACYTE, INC. - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Revenue: $150.3 million, up 15% year-over-year (Q2 2025: $130.2 million) • Testin | 2026-07-30 |
| Board / officer change · Q2 2026 VERACYTE, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • 3,500,000 additional shares approved for issuance under the 2023 Equity Incentive Plan • 9 dire | 2026-06-11 |
| Quarterly report · Q1 2026 VERACYTE, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Total Revenue Q1 2026: $139.1 million (up 21% vs. Q1 2025: $114.5 million) • Testing Revenue: $1 | 2026-05-06 |
| Results announced · Q2 2026 VERACYTE Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Revenue: $139.1 million, up 21% year-over-year (Q1 2025: $114.5 million) • Testi | 2026-05-05 |
| Proxy statement · Q2 2026 VERACYTE, INC. – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION • Marc Stapley (CEO) total 2025 compensation: Not specified in provided document sect | 2026-04-22 |
| Board / officer change · Q1 2026 VERACYTE, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial performance metrics disclosed in this filing BUSINESS & SEGMENT HIGHLIGHTS • Com | 2026-03-16 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquired Convergent Genomics for $150 million in cash plus milestones Veracyte, Inc. completed its acquisition of Convergent Genomics Inc. on September 14, 2026. Veracyte paid $150 million in upfront cash consideration, with potential for an additional $30 mil | 2026-09-14 |
| FY2025 revenue and adjusted EBITDA margin guidance provided Veracyte, a diagnostic testing company, announced preliminary 2025 financial results on January 11, 2026. For Q4 2025, the company expects total revenue of $138-$140 million (testing revenue | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Veracyte Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.